Adamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
August 24, 2017 16:16 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine)...
Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results
August 08, 2017 16:01 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the second quarter ended June 30, 2017. ...
Adamas to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8, 2017
August 01, 2017 14:33 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report second quarter 2017 financial results on Tuesday, August...
Adamas Appoints New Chief Financial Officer
June 28, 2017 09:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif, June 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Alfred G. Merriweather as Chief Financial Officer, reporting to...
Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
June 19, 2017 21:46 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology
June 12, 2017 16:01 ET
|
Adamas Pharmaceuticals, Inc.
--Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson’s Disease Patients with Levodopa-induced Dyskinesia -- --...
Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks
June 08, 2017 16:10 ET
|
Adamas Pharmaceuticals, Inc.
-- New subgroup analyses showed that patients previously treated with amantadine IR received benefit of ADS-5102 comparable to patients previously treated with placebo -- -- New Drug Application...
Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners
May 11, 2017 09:11 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it has entered into a $100 million royalty-backed note agreement with HealthCare...
Adamas Reports Recent Achievements and First Quarter 2017 Financial Results
May 09, 2017 16:01 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the first quarter ended March 31, 2017. ...
Adamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017
May 02, 2017 16:06 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2017 financial results on Tuesday, May 9,...